AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winklhofer-Roob, B. M.
Right arrow Articles by Shmerling, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winklhofer-Roob, B. M.
Right arrow Articles by Shmerling, D. H.
Agricola
Right arrow Articles by Winklhofer-Roob, B. M.
Right arrow Articles by Shmerling, D. H.

American Journal of Clinical Nutrition, Vol 63, 717-721, Copyright © 1996 by The American Society for Clinical Nutrition, Inc


ORIGINAL RESEARCH COMMUNICATIONS

Response to a single oral dose of all-rac-alpha-tocopheryl acetate in patients with cystic fibrosis and in healthy individuals

BM Winklhofer-Roob, PE Tuchschmid, L Molinari and DH Shmerling
Division of Gastroenterology and Nutrition, Department of Pediatrics, University of Zurich, Switzerland.

Biochemical vitamin E deficiency and low plasma lipids are frequent findings in patients with cystic fibrosis (CF). The response to a single oral dose of all-rac-alpha-tocopheryl acetate [100 IU (100 mg)/kg body wt] was studied over 24 h in 25 CF patients with exocrine pancreatic insufficiency and in 23 healthy individuals. Patients received pancreatic enzymes together with the vitamin E test dose. At baseline, plasma alpha-tocopherol concentrations correlated with cholesterol concentrations; both were lower in patients than in control subjects, as were erythrocyte alpha-tocopherol concentrations (all P < 0.0001). Plasma and erythrocyte alpha-tocopherol concentrations were significantly higher than baseline concentrations from 3 and 6 h onward, respectively, and peaked most frequently at 6 and 12 h, respectively, in both patients and control subjects. Maximum increases and areas under the concentration time curves for plasma alpha- tocopherol concentrations were smaller in patients than in control subjects (P < 0.0001). When ratios of plasma alpha-tocopherol to cholesterol (to correct for differences in cholesterol concentrations) or erythrocyte alpha-tocopherol concentrations were applied, patients were shown to respond as efficiently as control subjects. On the basis of these results, we recommend vitamin E supplements in doses high enough to achieve vitamin E status in CF patients well within the range of healthy individuals; these supplements should be given with appropriate amounts of pancreatic enzymes. However, for long-term supplementation much lower doses than those used in this test situation may be sufficient.


This article has been cited by other articles:


Home page
Am. J. Clin. Nutr.Home page
R. Brigelius-Flohe, F. J Kelly, J. T Salonen, J. Neuzil, J.-M. Zingg, and A. Azzi
The European perspective on vitamin E: current knowledge and future research
Am. J. Clinical Nutrition, October 1, 2002; 76(4): 703 - 716.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
R. K Lark, G. E Lester, D. A Ontjes, A. D Blackwood, B. W Hollis, M. M Hensler, and R. M Aris
Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients
Am. J. Clinical Nutrition, March 1, 2001; 73(3): 602 - 606.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by The American Society for Nutrition